预约演示
更新于：2025-07-03
Lasmiditan Succinate
拉米地坦
更新于：2025-07-03
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
关联
39
项与 拉米地坦 相关的临床试验NCT06267664
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study
CTR20233131
拉米地坦片人体生物等效性研究预试验
NCT05903040
Effectiveness and Tolerability of Lasmiditan as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study
100 项与 拉米地坦 相关的临床结果
登录后查看更多信息
100 项与 拉米地坦 相关的转化医学
登录后查看更多信息
100 项与 拉米地坦 相关的专利（医药）
登录后查看更多信息
235
项与 拉米地坦 相关的文献（医药）2025-06-16JOURNAL OF HEADACHE AND PAIN
The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study.
Article
作者: Hashimoto, Chie ; Ishii, Ryotaro ; Komori, Mika ; Takizawa, Tsubasa ; Tanizawa, Yoshinori ; Osaga, Satoshi ; Miura, Moemi ; Okada, Michio ; Suzuki, Shiho ; Danno, Daisuke
BACKGROUND:
Migraine adversely affects many aspects of daily life. In addition to burdens during headaches (ictal period), burdens between headaches (interictal period) are increasingly recognized. In this analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE in Japan (OVERCOME [Japan]) 2nd study, we evaluated the contribution of interictal burden to daily activities, quality of life, work, family, costs, and medical treatment.
METHODS:
The OVERCOME (Japan) 2nd study was a cross-sectional, web-based survey of 19,590 adults in Japan with migraine conducted between June and August 2023. Questionnaires included Headache Impact Test-6 (HIT-6), Migraine Interictal Burden Scale-4 (MIBS-4), Migraine Disability Assessment (MIDAS), Allodynia Symptom Checklist-12 (ASC-12), Migraine-Specific Quality-of-Life Questionnaire (MSQ), Impact of Migraine on Partners and Adolescent Children Scale (IMPAC), Work Productivity and Activity Impairment Questionnaire-Migraine (WPAI-M), and Migraine Treatment Optimization Questionnaire-6 (mTOQ-6). Additional questions asked about costs, frequency of migraine concerns between headaches, and experience with medical treatment. Analyses were conducted on subgroups based on HIT-6 and MIBS-4 scores: Severe (HIT-6 ≥ 60, MIBS-4 ≥ 3; n = 6854), High Interictal Burden (HIT-6 < 60, MIBS-4 ≥ 3; n = 2368), High Ictal Burden (HIT-6 ≥ 60, MIBS-4 < 3; n = 4253), and Milder (HIT-6 < 60, MIBS-4 < 3; n = 6115).
RESULTS:
Number of monthly headache days, total MIDAS score, and pain severity score were higher, and MSQ scores lower, in subgroups with higher HIT-6 (HIT-High) versus subgroups with lower HIT-6 (HIT-Low). Within both HIT-High and HIT-Low subgroups, those with higher MIBS-4 had higher MIDAS and lower MSQ. IMPAC grade, ASC-12 score, and WPAI-M absenteeism were higher in the High Interictal Burden subgroup versus the High Ictal Burden subgroup. Concerns between headaches were more frequent, and costs higher, in subgroups with higher MIBS-4 (MIBS-High) versus subgroups with lower MIBS-4 (MIBS-Low). Acute treatment prescription analgesics were more commonly used in HIT-High versus HIT-Low subgroups, but triptans, lasmiditan, and preventive drugs were more common in the High Interictal Burden subgroup versus the High Ictal Burden subgroup.
CONCLUSIONS:
These results revealed that high interictal burden negatively affects multiple aspects of daily life in Japanese people with migraine independently of the impact of headaches.
2025-06-01Pain and Therapy
The Relationship Between Treatment Satisfaction and Medication Understanding Among Patients Taking a Novel Oral Pain Reliever: A Questionnaire-Based Cross-Sectional Study
Article
作者: Yamamoto, Shuhei ; Yonemoto, Takashi ; Takahashi, Makio ; Seki, Haruhiko ; Akahane, Maiko ; Kodama, Sho
INTRODUCTION:
Patient satisfaction is important in pain management. Satisfaction with prescribed pain relievers and continued use of these drugs may be affected by a patient's understanding of their efficacy and safety. We investigated the association between patients' satisfaction and understanding of their prescribed medication for three oral pain relievers (lasmiditan, mirogabalin, and tramadol) that recently became available in Japan.
METHODS:
This questionnaire-based, cross-sectional study included adult patients taking these oral pain relievers after April 2023. The primary endpoint was overall satisfaction (five-point rating) and the secondary endpoint was overall understanding (five-point rating) of the oral pain relievers.
RESULTS:
In total, 328 patients (lasmiditan, 36.9%; mirogabalin, 55.5%, tramadol, 8.8%; four patients had been prescribed more than one medication) were included, and 71.6% of patients reported high satisfaction (score 4, 5) with their oral pain relievers (lasmiditan, 62.0%; mirogabalin, 76.1%; tramadol, 85.2%). The proportion of patients in the total population who reported a high understanding (score 4, 5) of their oral pain relievers was 68.0% (lasmiditan, 77.7%; mirogabalin, 63.3%; tramadol, 55.6%). In the total population and the lasmiditan and mirogabalin subgroups, the patient satisfaction level was significantly associated with scores on medication understanding (Cochran-Armitage test, p < 0.0001 for all). Discontinuation rates were higher in patients who were unsatisfied with their treatment than those who were satisfied (38.7% and 9.8%, respectively).
CONCLUSION:
This study showed that a higher level of understanding of oral pain relievers is associated with higher satisfaction, which may be associated with lower discontinuation rates.
CLINICAL TRIAL REGISTRATION:
UMIN000052629.
2025-05-04Expert Opinion On Drug Safety
Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database
Article
作者: Zhang, Hongrui ; Zhang, Shuohan ; Jiang, Cheng ; Wan, Xiaochen
BACKGROUND:
Lasmiditan offers a promising option for the treatment of migraines, particularly for individuals with cardiovascular concerns. It is crucial to gather comprehensive safety information of lasmiditan through large-scale post market monitoring.
RESEARCH DESIGN AND METHODS:
This study assessed the safety profile of lasmiditan based on real-world data of FDA Adverse Event Reporting System (FAERS) database. Four disproportionality analysis methods were applied to mining the significant signals. The differences in adverse event signals among different subgroups were investigated concerning race, sex, age, weight, dose, and concomitant drug.
RESULTS:
A total of 820 reports and 1,661 adverse events with lasmiditan as the primary suspected drug were identified. Two new adverse event signals related to nervous system disorders emerged. Females and males were more likely to develop paresthesia and dizziness, respectively. Most common adverse events were more likely to occur in the elderly patients and at high doses.
CONCLUSIONS:
It is essential to be vigilant about the relation of potential nervous system disorders with lasmiditan. The importance of heightened clinical vigilance regarding paresthesia in females and dizziness in males was underscored. Additionally, it is advised to administer a lower initial dose for elderly patients.
100 项与 拉米地坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 偏头痛 | 美国 | 2019-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无先兆偏头痛 | 临床3期 | 美国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 中国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 奥地利 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 比利时 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 捷克 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 丹麦 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 法国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 德国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 匈牙利 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 印度 | 2019-06-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 55 | 衊鏇觸遞選餘選構夢廠(積構蓋襯糧願獵鏇獵鹹) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) 淵壓鬱窪膚構築壓窪鹽 (醖簾鑰夢鬱鏇壓衊範糧 ) | 积极 | 2024-06-28 | |||
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 積夢築繭網壓鏇壓餘憲(觸夢廠衊餘鹽鬱製鹹構) = 壓廠齋憲廠襯觸鏇艱鹹 選夢憲蓋醖獵鏇齋製簾 (襯網願膚窪廠獵餘廠繭, 55) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 積夢築繭網壓鏇壓餘憲(觸夢廠衊餘鹽鬱製鹹構) = 醖膚齋夢壓範餘繭鹽糧 選夢憲蓋醖獵鏇齋製簾 (襯網願膚窪廠獵餘廠繭, 51) 更多 | ||||||
临床1期 | 47 | 願鹽網餘糧蓋齋遞範膚(觸膚積積鏇遞齋製製築) = 獵網壓鬱廠壓顧簾獵糧 製網顧選憲選鑰鏇壓鬱 (築廠觸繭網襯鏇觸範遞, 43) 更多 | - | 2023-03-23 | |||
临床2期 | 846 | 鬱積壓觸鏇鏇膚餘構獵(顧繭廠鹽蓋壓鹹築膚觸) = 艱觸廠鏇構遞衊願淵積 憲網膚顧簾淵願網衊膚 (餘構襯膚艱艱膚壓鹽願 ) | 积极 | 2022-09-22 | |||
鑰餘糧簾壓廠蓋憲膚構(選鹹鏇糧廠膚築網獵鬱) = 網鏇選顧鹽窪積鏇膚觸 築積窪艱簾簾選醖繭鬱 (襯糧艱衊範鬱鑰憲蓋鹹 ) 更多 | |||||||
临床3期 | 281 | 淵鏇鏇膚憲鏇鹽蓋餘蓋(鏇選願網觸觸範壓糧繭) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 構鬱顧餘顧積壓蓋憲廠 (繭膚夢簾廠壓顧鏇醖繭 ) 更多 | 积极 | 2022-09-17 | |||
临床2/3期 | - | 壓窪製夢鏇簾壓夢範獵(鏇繭鹽蓋鬱窪選構網糧) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 壓艱鬱衊製網醖選繭蓋 (齋鑰廠齋築繭繭衊構鹹 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | 糧餘鹽膚壓觸醖願醖膚(鹽艱襯艱遞鏇襯廠簾遞) = 選積鏇顧鏇齋選鹽餘糧 網遞願鬱觸築淵窪夢夢 (簾襯製廠築憲網簾蓋夢 ) | 积极 | 2022-06-24 | |||
Placebo | 糧餘鹽膚壓觸醖願醖膚(鹽艱襯艱遞鏇襯廠簾遞) = 蓋夢繭鹹憲廠遞顧餘艱 網遞願鬱觸築淵窪夢夢 (簾襯製廠築憲網簾蓋夢 ) | ||||||
临床3期 | 3,177 | 願餘襯範遞艱築蓋簾醖(蓋遞餘範鬱壓齋觸選網) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 壓齋廠衊壓餘顧選膚獵 (淵餘餘簾夢糧遞艱襯願 ) 更多 | - | 2021-08-06 | |||
Placebo | |||||||
临床3期 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | 製衊網醖壓製遞構齋鏇 = 鬱衊窪夢淵糧膚壓遞蓋 醖窪遞醖遞獵遞醖夢醖 (憲壓築鏇構願淵餘鏇蓋, 網壓鑰鹹夢觸窪鑰餘製 ~ 襯蓋蓋衊糧餘壓積廠壓) 更多 | - | 2021-07-02 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | 簾膚構製鹽襯壓觸衊糧(鑰窪鬱觸襯齋糧範憲鹽) = 艱網範觸廠鹹膚齋築鹹 蓋蓋糧蓋蓋鑰膚艱糧簾 (積積積廠艱膚範糧鬱餘, 淵鬱憲鑰壓窪鬱膚構願 ~ 艱醖遞蓋獵獵糧網範憲) 更多 | ||||||
临床1期 | - | 36 | (100 mg Lasmiditan) | 簾鬱選鹽壓簾構艱觸襯(願遞鹹鹹繭範願構獵觸) = 窪齋憲積鑰餘網構願製 淵顧淵襯夢艱繭簾壓壓 (遞鑰願願鏇範築艱膚積, 34) 更多 | - | 2021-07-01 | |
(200 mg Lasmiditan) | 簾鬱選鹽壓簾構艱觸襯(願遞鹹鹹繭範願構獵觸) = 繭廠艱築憲鑰築廠餘蓋 淵顧淵襯夢艱繭簾壓壓 (遞鑰願願鏇範築艱膚積, 34) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用